28 results
424B5
IMPL
Impel Pharmaceuticals Inc
5 Oct 23
Prospectus supplement for primary offering
5:19pm
may lead to the loss of intellectual property protection. Any such breach or other incident may result in significant costs to remediate … incident may result in potential regulatory actions or litigation, including material claims for damages, interruption to our operations, delays
10-K/A
2022 FY
EX-3.2
IMPL
Impel Pharmaceuticals Inc
31 Mar 23
Annual report (amended)
4:21pm
all powers that are commonly incident to the office of President or that are delegated to the President by the Board.
Section 4.6: Chief Financial … shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer, or as the Board or the Chief Executive
S-3
EX-1.2
rztf9e95lq5r
16 May 22
Shelf registration
4:49pm
10-K
gud54kfvvq8dblvp
29 Mar 22
Annual report
5:09pm
424B4
8z0e4rdi2berya 8ebx2
10 Sep 21
Prospectus supplement with pricing info
4:01pm
DRS
seng0ubcdo a8728
25 Aug 21
Draft registration statement
12:00am
10-Q
EX-3.2
2lqupm
7 Jun 21
Quarterly report
7:17am
10-Q
ihc6k4l7
7 Jun 21
Quarterly report
7:17am
424B1
e3b qhqaai
23 Apr 21
Prospectus with pricing info
4:01pm